Here you will find the recommendations we have made about the use of individual medicines in Lancashire.


Brand: Skyrizi ®
NICE TA: 596
Indication: Risankizumab for treating moderate to severe plaque psoriasis (NICE TA596)
Disease category: Skin
Commissioning responsibility: CCG
PbR excluded: Yes


1.1 Risankizumab is recommended as an option for treating plaque psoriasis in adults, only if:
• the disease is severe, as defined by a total Psoriasis Area and Severity Index (PASI) of 10 or more anda Dermatology Life
Quality Index (DLQI) of more than 10 and • the disease has not responded to other systemic treatments, including ciclosporin, methotrexate and phototherapy, or
these options are contraindicated or not tolerated and
• the company provides the drug according to the commercial arrangement.


LMMG recommendation: Red
Click here to find the definitions for the colour classifications

Reason for decision:  Specialist medicine

Supporting documents:

NICE TA596 - Risankizumab for treating moderate to severe plaque psoriasis

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG